XYREM (Sodium oxybate) Drug Insight and Market Forecast - 2032

“XYREM (Sodium oxybate) Drug Insight and Market Forecast - 2032” report provides comprehensive insights about XYREM (Sodium oxybate) for Excessive Daytime Sleepiness (EDS) in the 7MM. A detailed picture of the XYREM (Sodium oxybate) for Excessive Daytime Sleepiness (EDS) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the XYREM (Sodium oxybate) for Excessive Daytime Sleepiness (EDS) . The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XYREM (Sodium oxybate) market forecast, analysis for Excessive Daytime Sleepiness (EDS) in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Excessive Daytime Sleepiness (EDS).

Drug Summary

The US FDA approved XYREM (sodium oxybate) oral solution, CIII, for both cataplexy and Excessive Daytime Sleepiness (EDS) in narcolepsy in adult and pediatric patients ages 7 and older. XYREM was first approved in the US in 2002, based on clinical trial data in adults. It was also approved in the EU for the treatment of cataplexy in adult patients with narcolepsy. The generic of XYREM is supposed to enter the market in 2023.

Dosage
Dosage for Adult Patients

• Initiate dosage at 4.5 g per night orally divided into two doses
• Titrate to effect in increments of 1.5 g per night at weekly intervals (0.75 g at bedtime and 0.75 g taken 2.5-4 h later)
• Recommended dosage range: 6-9 g per night orally

Dosage for Pediatric Patients (7 years of age and older)

• The recommended starting dosage, titration regimen, and maximum total nightly dosage are based on body weight.

Mechanism of Action
XYREM is a CNS depressant. The mechanism of action of XYREM in the treatment of narcolepsy is unknown. Sodium oxybate is the sodium salt of Gamma-hydroxybutyrate (GHB), an endogenous compound and metabolite of the neurotransmitter GABA. It is hypothesized that the therapeutic effects of XYREM on cataplexy and EDS are mediated through GABAB actions on noradrenergic and dopaminergic neurons as well as on thalamocortical neurons.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the XYREM (Sodium oxybate) description, mechanism of action, dosage and administration, research and development activities in Excessive Daytime Sleepiness (EDS).
• Elaborated details on XYREM (Sodium oxybate) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the XYREM (Sodium oxybate) research and development activity in Excessive Daytime Sleepiness (EDS) in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around XYREM (Sodium oxybate).
• The report contains forecasted sales of XYREM (Sodium oxybate) for Excessive Daytime Sleepiness (EDS) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Excessive Daytime Sleepiness (EDS).
• The report also features the SWOT analysis with analyst views for XYREM (Sodium oxybate) in Excessive Daytime Sleepiness (EDS).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XYREM (Sodium oxybate) Analytical Perspective

In-depth XYREM (Sodium oxybate) Market Assessment

This report provides a detailed market assessment of XYREM (Sodium oxybate) in Excessive Daytime Sleepiness (EDS) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

XYREM (Sodium oxybate) Clinical Assessment

The report provides the clinical trials information of XYREM (Sodium oxybate) in Excessive Daytime Sleepiness (EDS) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Excessive Daytime Sleepiness (EDS) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XYREM (Sodium oxybate) dominance.
• Other emerging products for Excessive Daytime Sleepiness (EDS) are expected to give tough market competition to XYREM (Sodium oxybate) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XYREM (Sodium oxybate) in Excessive Daytime Sleepiness (EDS).
• Our in-depth analysis of the forecasted sales data of XYREM (Sodium oxybate) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XYREM (Sodium oxybate) in Excessive Daytime Sleepiness (EDS).

Key Questions Answered

• What is the product type, route of administration and mechanism of action of XYREM (Sodium oxybate)?
• What is the clinical trial status of the study related to XYREM (Sodium oxybate) in Excessive Daytime Sleepiness (EDS) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XYREM (Sodium oxybate) development?
• What are the key designations that have been granted to XYREM (Sodium oxybate) for Excessive Daytime Sleepiness (EDS)?
• What is the forecasted market scenario of XYREM (Sodium oxybate) for Excessive Daytime Sleepiness (EDS)?
• What are the forecasted sales of XYREM (Sodium oxybate) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Excessive Daytime Sleepiness (EDS) and how are they giving competition to XYREM (Sodium oxybate) for Excessive Daytime Sleepiness (EDS)?
• Which are the late-stage emerging therapies under development for the treatment of Excessive Daytime Sleepiness (EDS)?